[CLINICAL EVALUATION OF THERAPEUTIC EFFECT PREDICTORS IN PEMBROLIZUMAB FOR ADVANCED UROTHELIAL CANCER]

Yoshitaka Itami1,2, Chihiro Omori1, Motokiyo Yoshikawa1

  • 1Department of Urology, Nara Prefecture General Medical Center.

Summary

Pembrolizumab shows efficacy in advanced urothelial cancer, with overall survival of 8.8 months. High TSH levels before treatment may indicate hypothyroidism and suggest a potentially improved prognosis.